BACKGROUND: Emerging evidence shows that nanomechanical phenotypes of circulating tumor cells (CTC) could become potential biomarkers for metastatic castration resistant prostate cancer (mCRPC). METHODS: To determine the nanomechanical phenotypes of CTCs we applied atomic force microscopy (AFM) employing the PeakForce quantitative nanomechanical (QNM) imaging. We assessed biophysical parameters (elasticity, deformation, and adhesion) of 130 CTCs isolated from blood samples from five castration sensitive (CS) and 12 castration resistant prostate cancer (CRPCa) patients. RESULTS: We found that CTCs from CRPCa patients are three times softer, three times more deformable, and seven times more adhesive than counterparts from CSPCa patients. Both nonsupervised hierarchical clustering and principle component analysis show that three combined nanomechanical parameters could constitute a valuable set to distinguish between CSPCa and CRPCa. CONCLUSIONS: [corrected] Our study indicates that nanomechanical phenotypes of CTCs may serve as novel and effective biomarkers for mCRPC.
BACKGROUND: Emerging evidence shows that nanomechanical phenotypes of circulating tumor cells (CTC) could become potential biomarkers for metastatic castration resistant prostate cancer (mCRPC). METHODS: To determine the nanomechanical phenotypes of CTCs we applied atomic force microscopy (AFM) employing the PeakForce quantitative nanomechanical (QNM) imaging. We assessed biophysical parameters (elasticity, deformation, and adhesion) of 130 CTCs isolated from blood samples from five castration sensitive (CS) and 12 castration resistant prostate cancer (CRPCa) patients. RESULTS: We found that CTCs from CRPCa patients are three times softer, three times more deformable, and seven times more adhesive than counterparts from CSPCa patients. Both nonsupervised hierarchical clustering and principle component analysis show that three combined nanomechanical parameters could constitute a valuable set to distinguish between CSPCa and CRPCa. CONCLUSIONS: [corrected] Our study indicates that nanomechanical phenotypes of CTCs may serve as novel and effective biomarkers for mCRPC.
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Ya-Ting Hsu; Pawel Osmulski; Yao Wang; Yi-Wen Huang; Lu Liu; Jianhua Ruan; Victor X Jin; Nameer B Kirma; Maria E Gaczynska; Tim Hui-Ming Huang Journal: Cancer Res Date: 2016-08-28 Impact factor: 12.701
Authors: Josephine Shaw Bagnall; Sangwon Byun; David T Miyamoto; Joon Ho Kang; Shyamala Maheswaran; Shannon L Stott; Mehmet Toner; Scott R Manalis Journal: Integr Biol (Camb) Date: 2016-03-21 Impact factor: 2.192
Authors: Pawel A Osmulski; Alessandra Cunsolo; Meizhen Chen; Yusheng Qian; Chun-Lin Lin; Chia-Nung Hung; Devalingam Mahalingam; Nameer B Kirma; Chun-Liang Chen; Josephine A Taverna; Michael A Liss; Ian M Thompson; Tim H-M Huang; Maria E Gaczynska Journal: Cancer Res Date: 2021-05-27 Impact factor: 12.701
Authors: Benjamin Sunkel; Dayong Wu; Zhong Chen; Chiou-Miin Wang; Xiangtao Liu; Zhenqing Ye; Aaron M Horning; Joseph Liu; Devalingam Mahalingam; Horacio Lopez-Nicora; Chun-Lin Lin; Paul J Goodfellow; Steven K Clinton; Victor X Jin; Chun-Liang Chen; Tim H-M Huang; Qianben Wang Journal: Nucleic Acids Res Date: 2016-01-06 Impact factor: 16.971
Authors: Josephine Shaw Bagnall; Sangwon Byun; Shahinoor Begum; David T Miyamoto; Vivian C Hecht; Shyamala Maheswaran; Shannon L Stott; Mehmet Toner; Richard O Hynes; Scott R Manalis Journal: Sci Rep Date: 2015-12-18 Impact factor: 4.379